- Home
- GOSS
GOSS
Gossamer Bio Inc.
as 07-26-2024 4:00pm EST
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 246.6M | IPO Year: | 2019 |
| Target Price: | $9.20 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.45 - $1.60 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -96.96% |
Stock Insider Trading Activity of Gossamer Bio Inc. (GOSS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aranda Richard | GOSS | Chief Medical Officer | Jun 24 '24 | Sell | $0.66 | 1,908 | $1,260.23 | 196,891 | SEC Form 4 |
| Hasnain Faheem | GOSS | President & CEO | Jun 21 '24 | Buy | $0.67 | 372,000 | $250,281.60 | 5,408,073 | SEC Form 4 |
| Giraudo Bryan | GOSS | COO/CFO | Jun 18 '24 | Buy | $0.59 | 100,000 | $59,110.00 | 480,010 | SEC Form 4 |
| Smith Robert Paul JR | GOSS | Chief Commercial Officer | Jun 17 '24 | Buy | $0.60 | 25,000 | $15,050.00 | 25,000 | SEC Form 4 |
| Christian Waage | GOSS | EVP, Tech Ops and Admin | Mar 27 '24 | Sell | $1.16 | 6,430 | $7,429.87 | 585,934 | SEC Form 4 |
| Giraudo Bryan | GOSS | COO/CFO | Mar 27 '24 | Sell | $1.16 | 6,430 | $7,430.51 | 92,737 | SEC Form 4 |
| Hasnain Faheem | GOSS | President & CEO | Mar 27 '24 | Sell | $1.16 | 23,172 | $26,772.93 | 120,293 | SEC Form 4 |
| Aranda Richard | GOSS | Chief Medical Officer | Mar 18 '24 | Sell | $1.33 | 4,018 | $5,341.93 | 198,799 | SEC Form 4 |
| Peterson Caryn | GOSS | EVP, Regulatory Affairs | Mar 18 '24 | Sell | $1.33 | 4,018 | $5,342.73 | 49,833 | SEC Form 4 |
Latest Gossamer Bio Inc. News
GOSS Breaking Stock News: Dive into GOSS Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now?
MT Newswires
a month ago
Oppenheimer Initiates Gossamer Bio at Outperform With $9 Price Target
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Compare GOSS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GOSS Gossamer Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.